BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Gryphon Therapeutics (Formerly Gryphon Sciences) 

600 Gateway Blvd.

South San Francisco  California  94080  U.S.A.
Phone: 650-952-7714 Fax: 650-952-3055


SEARCH JOBS
Protein therapeutics have emerged as one of the most promising and profitable segments of the pharmaceutical markets since the introduction of recombinant insulin in 1982. Companies have focused on the production of monoclonal and polyclonal antibodies, therapeutic vaccines, proteins isolated from human tissue or blood, and recombinant proteins as ways of producing products in this sector. Gryphon has taken an entirely different approach. Thanks to advances by its team of scientists, Gryphon can generate novel or improved protein therapeutics using chemistry alone. This positions Gryphon to benefit from the revolution in genomics and proteomics that has identified countless new potential protein therapeutics. Gryphon uses two technologies that allow it to rapidly produce proteins of medical interest. These technologies form a powerful drug development platform, which Gryphon has used to address large commercial markets. Our products combine chemically synthesized protein backbones with precision polyethylene glycol (pPEG) like molecules to create potent medications. The use of chemistry, rather than biology, allows us to manipulate protein drugs in ways that were never before possible. Gryphon has introduced changes to the molecules, which result in their increased potency, and duration in the circulatory system. Efficient-scalable processes with high yields make this a cost effective way to manufacture valuable drugs. In the short term, Gryphon will out-license its products to pharmaceutical partners. We will successively move our projects farther into the clinical development process in order to increase the value of the licensing opportunities. Ultimately, Gryphon will commercialize select products on its own.

Last Updated: 07-08-03


 Key Statistics


Email: info@gryphonrx.com
Ownership: Private

Web Site: Gryphon Therapeutics (Formerly Gryphon Sciences)
Employees: 30
Symbol: 
 









 Company News
Gryphon Therapeutics's Technology Featured In Scientific American 10/19/2005 5:10:44 PM    More...

//-->